Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to AGO's second quarter 2025 conference call. At this time all participants are in a listen-only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at AGO's request. I would now like to turn the call over to AGO. Please go ahead. Thank you, operator. Good morning, everyone. I'm Morgan Sanford, vice president of Investor at AGO. Thank you for joining us to discuss AGO's pharmaceuticals second quarter 2025 financial results and business highlights. You can access the slides for today's call by going to the investor section of our website, AGO.com. Please move to the next slide. Today we'll be making certain forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements. Because of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. Next slide, please. On the call with me today from AGO are Brian Goff, chief executive officer, Cecilia Jones, chief financial officer, Sveta Milanova, chief commercial officer, and Dr. Sarah Hewens, chief medical officer and head of research and development. Following prepared remarks, we will open the call for questions. With that, please move to the next slide and I am pleased to turn the call over to Brian. Thanks, Morgan. Good morning, everyone, and thank you for joining us on today's call. Next slide, please. 2025 is shaping up to be a breakout year for AGOs and we believe we have a clear path to deliver sustainable growth and unlock long-term shareholder value. First, we have a TK activator, Pyrokin. Second, momentum is building as we approach multi...